Form 4: Alkermes VP of Finance, Samuel Joseph Parisi, Reports Transactions in Company Stock

Samuel Joseph Parisi, VP of Finance (Interim PAO) at Alkermes plc, reports acquisition and disposal of ordinary shares and derivative securities.

Summary

• Samuel Joseph Parisi, VP of Finance (Interim PAO) at Alkermes plc, filed a Form 4 detailing changes in beneficial ownership.
• On February 23, 2024, Parisi acquired 2,283 ordinary shares through the vesting of restricted stock units.
• Also on February 23, 2024, Parisi disposed of 672 ordinary shares at $29.57 to cover tax obligations.
• On February 27, 2024, Parisi sold 2,559 ordinary shares at $29.65.
• Parisi also acquired 20,890 employee stock options and 10,986 restricted stock units on February 26, 2024.
• Following these transactions, Parisi directly owns 7,717 ordinary shares, 6,851 restricted stock units, and 20,890 employee stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing primarily reflects routine transactions related to stock options and restricted stock units, with a small sale of shares. It doesn't strongly indicate positive or negative sentiment.

Positives

• The acquisition of 20,890 employee stock options and 10,986 restricted stock units indicates confidence in the company's future performance.

Negatives

• The sale of 2,559 ordinary shares on February 27, 2024, could be interpreted negatively, although it may be for personal financial reasons.

Risks

• Executive stock sales can sometimes signal a lack of confidence in the company's future prospects, although this is not necessarily the case here.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• The vesting schedules for the restricted stock units and stock options (four equal annual installments) are fairly standard in the industry.
• Similar to other pharmaceutical companies, Alkermes uses equity-based compensation to attract and retain key personnel.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as they provide insight into the actions of a key executive.
• The disposal of shares to cover tax obligations is a common practice and is unlikely to significantly affect stakeholder confidence.

Key Dates